



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, G01N 33/566	A2	(11) International Publication Number: WO 99/29319 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/DK98/00489 (22) International Filing Date: 13 November 1998 (13.11.98) (30) Priority Data: 1433/97 9 December 1997 (09.12.97) DK (71) Applicant (for all designated States except US): NEUROSEARCH A/S [DK/DK]; Smedeland 26B, DK-2600 Glostrup (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): VARMING, Thomas [DK/DK]; NeuroSearch a/s, Smedeland 26B, DK-2600 Glostrup (DK). (74) Common Representative: NEUROSEARCH A/S; Patent Dept., Smedeland 26B, DK-2600 Glostrup (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: CHEMICAL COMPOUNDS FOR USE AS ANXIOLYTIC AGENTS AND A METHOD FOR THE IDENTIFICATION OF ANXIOLYTIC COMPOUNDS (57) Abstract This invention relates to a particular group of chemical compounds for use as non-sedative anxiolytic drugs, and a method for the identification of chemical compounds with anxiolytic potential.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CHEMICAL COMPOUNDS FOR USE AS ANXIOLYTIC AGENTS AND A METHOD FOR THE IDENTIFICATION OF ANXIOLYTIC COMPOUNDS

5

TECHNICAL FIELD

This invention relates to a particular group of chemical compounds for use as non-sedative anxiolytic drugs, and a method for the identification of chemical compounds with anxiolytic potential.

10

BACKGROUND ART

Receptors for the major inhibitory neurotransmitter, γ -aminobutyric acid (GABA), are divided into two main classes, GABA_A receptors and GABA_B receptors.

15 GABA_A receptors are members of a ligand-gated ion channel family, and are the most abundant inhibitory receptors in the mammalian brain. Each GABA_A receptor complex comprises a chloride ion channel that controls the chloride flux across the neuronal membrane, along with multiple recognition sites for small modulatory molecules such as benzodiazepines, barbiturates, picrotoxin, and certain
20 steroids. When GABA interacts with its receptor, the ion channel is opened, the chloride flux is enhanced, and the cell becomes less responsive to excitatory stimuli. This GABA induced ion current can be regulated by various agents, including agents that interact with the benzodiazepine receptor or recognition site.

Agents that bind or interact with the modulatory sites on the GABA_A
25 receptor complex, e.g. the benzodiazepine receptor, and have a positive modulatory effect on the action of GABA, are called benzodiazepine receptor agonists or partial agonists. Agonists generally produce muscle relaxant, hypnotic, sedative, anxiolytic, and/or anticonvulsant effects.

Benzodiazepine receptor ligands with negative modulatory effect on the
30 action of GABA are termed inverse agonists, while benzodiazepine receptor ligands with no intrinsic activity are termed antagonists.

The present invention resides in the surprising discovery that a particular chemical compound, 5-acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole O-ethyl oxime, in

addition to being a potent benzodiazepine receptor agonist, is also characterised by a remarkable capability to effectively potentiate responses evoked by lower concentrations of GABA, while inhibiting responses evoked by higher concentrations of GABA.

5

SUMMARY OF THE INVENTION

The present invention provides chemical compounds for use as non-sedative anxiolytic drugs, and pharmaceutical compositions comprising these
10 anxiolytic compounds.

Moreover, the present invention provides methods for the screening of chemical compounds for anxiolytic potential. More specifically it is an object of the present invention to provide a convenient tool for the identification of benzodiazepine receptor agonists or partial agonists, capable of exerting a positive modulation of the
15 GABA_A receptor complex, which benzodiazepine receptor agonists or partial agonists are devoid the sedative effects often encountered with conventional benzodiazepine receptor agonists.

Accordingly, in its first aspect, the invention relates to the use of a chemical compound for the manufacture of a pharmaceutical composition for the treatment of
20 anxiolytic disorders, which chemical compound potentiate responses evoked by lower concentrations of GABA, while inhibiting responses evoked by higher concentrations of GABA.

In another aspect the invention provides a method for the screening of chemical compounds for their potential as anxiolytic drugs, which method comprises
25 the steps of determining, in the presence of different concentrations of GABA, the electrophysiological response evoked by GABA on a GABA_A receptor; repeating the first step in the presence of a chemical compound to be screened; and selecting the chemical compounds that selectively potentiate responses evoked by GABA at lower concentrations.

30 In a further aspect, the invention provides chemical compounds capable of potentiating responses evoked by lower concentrations of GABA, while inhibiting responses evoked by higher concentrations of GABA, and the use of these compounds as non-sedative anxiolytic drugs.

Finally the invention provides pharmaceutical compositions comprising the chemical compound of the invention, and methods of treating anxiolytic disorders, by which methods a mammal, including a human, is treated with a chemical compound of the invention.

5

DETAILED DISCLOSURE OF THE INVENTION

The Chemical Compounds

The present invention resides in the surprising discovery that a particular
10 chemical compound, 5-acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole O-ethyl oxime, Compound 6 obtained as described in Ex. 1 (hereinafter referred to as Compound 6), in addition to being a potent benzodiazepine receptor agonist, is also characterised by a remarkable capability to potentiate the effect of GABA at low concentrations, while inhibiting the effect of GABA at higher concentrations. I.e. the effect of Compound 6 on
15 a GABA evoked response was dependent on the GABA concentration used.

This effect is considered unexpected because Compound 6, while being a benzodiazepine receptor agonists, in itself has a positive modulatory effect on the action of GABA, and because of this positive modulatory effect would be expected to show an effect that is additive to the effect of GABA or even synergistic, no matter at
20 what GABA concentration.

In particular it was noted that at low GABA concentrations (of from about 0.3 to about 1 μ M), Compound 6 show a 4-5 fold potentiation of the GABA response. This potentiation is higher than for the classic benzodiazepines. However, at higher stimulus intensity (at GABA concentrations of more than about 3 μ M), Compound 6
25 show little or no potentiation of GABA responses, and at very high GABA concentrations (of more than about 10 μ M), Compound 6 actually blocked GABA responses.

In other words, Compound 6, like the classical benzidoazepines, possesses a potentiating efficacy at lower concentrations of GABA, while this compound, in
30 contrast to the classical benzidoazepines, more quickly loses its potentiating efficacy at slightly higher concentrations of GABA, and ultimately, at high GABA concentrations, becomes an inhibitor of the GABA response.

The ability of Compound 6 to act as an efficient potentiator at relative low stimulus intensity while losing its efficacy at higher stimulus intensity is a very attractive property, and in this way Compound 6 is considered a representative for an entire group of chemical compounds that is particularly useful as non-sedative
5 anxiolytic drugs.

The group of chemical compounds contemplated according to this invention distinguish from the classical anxiolytic compounds and thus represents a novel and distinct group of anxiolytic compounds.

The chemical compounds of the invention is characterised by being a
10 chemical compound that, like the classical benzodiazepines, possesses a potentiating efficacy at lower concentrations of GABA, while, in contrast to the classical benzodiazepines, losing its potentiating efficacy at higher concentrations of GABA, and ultimately, at very high GABA concentrations, becomes an inhibitor of the GABA response.

15 In a preferred embodiment, the chemical compounds of the invention may be characterised by being any chemical compound, apart from Compound 6, which is capable of potentiating responses evoked by concentrations of GABA of below about 5 μM , preferably below about 3 μM , while inhibiting responses evoked by concentrations of GABA of above about 3 μM , preferably above about 5 μM .

20

A Method of Screening

Based on this finding, we now provide an efficient tool for use in the screening of new chemical compounds for their potential for use as anxiolytic drugs, in particular for use as non-sedative anxiolytic drugs.

25 According to the method of the invention the electrophysiological response evoked by GABA on a GABA_A receptor is determined at different concentrations of GABA and in the presence and absence of the compound to be tested.

After the electrophysiological response has been recorded, the response evoked by GABA alone is compared to that recorded in the presence of the compound
30 to be tested. According to the present invention, compounds capable of increasing the response evoked by GABA at lower concentrations of GABA are selected.

It is at present contemplated that the method shall be carried out at concentrations of GABA in the range of from about 0.001 μM to about 10,000 μM ,

preferably in the range of from about 0.01 μM to about 1000 μM , more preferred in the range of from about 0.1 μM to about 500 μM , most preferred of from about 0.3 μM to about 300 μM .

Also it is contemplated that chemical compounds that selectively potentiate
5 responses evoked by GABA at concentrations lower than 10 μM , preferably lower than 5 μM , most preferred lower than 3 μM , are selected.

Positive Modulatory Effect

As noted above, benzodiazepine receptor agonists or partial agonists are
10 agents having a positive modulatory effect on the response on GABA_A receptors evoked by the action of GABA. A positive modulatory response evoked on GABA_A receptors by the action of GABA may be measured using known electrophysiological methods, in particular the well known patch clamp technology.

In a preferred embodiment the response evoked on GABA_A receptors by the
15 action of GABA may be measured using whole-cell patch clamp electrophysiological methods.

Cells

The whole-cell patch clamp method may be applied to any cell holding a
20 GABA_A receptor.

In a preferred embodiment, the cell applied in this method is a CHO cell, a HEK cell, or a HeLa cell.

GABA_A Receptors

25 The GABA_A receptors are structurally constituted macromolecular heteropentameric assemblies, containing a combinations of α , β , and γ/δ protein subunits. Several subunits of such GABA_A receptors (α_{1-6} , β_{1-3} , δ and γ_{1-3}) have been characterised using techniques of modern molecular biology. By far the largest population (representing almost half of all GABA_A receptors in the brain) is that
30 containing the $\alpha 1$ subunit in combination with the $\beta 2$ and $\gamma 2$ subunits.

In a preferred embodiment, a receptor comprising an $\alpha 1$, an $\alpha 2$, an $\alpha 3$, an $\alpha 5$, or an $\alpha 6$ subunit; a $\beta 1$, a $\beta 2$, or a $\beta 3$ subunit; and a $\gamma 2\text{S}$ or a $\gamma 2\text{L}$ subunit, or any combination hereof, is employed.

Also $\alpha\beta\delta$ GABA_A receptor subunits, or $\alpha\beta\epsilon$ GABA_A receptor subunits may be employed.

According to the present invention the use of co-expression of the GABA_A receptor subunits $\alpha 1$, $\beta 2$ and $\gamma 2$ is found to be very useful. Also the $\alpha 1\beta 2\gamma 2L$; the $\alpha 1\beta 3\gamma 2L$; the $\alpha 2\beta 2\gamma 2L$; the $\alpha 2\beta 3\gamma 2L$; the $\alpha 3\beta 2\gamma 2L$; the $\alpha 3\beta 3\gamma 2L$; the $\alpha 5\beta 2\gamma 2L$; the $\alpha 5\beta 3\gamma 2L$; the $\alpha 6\beta 2\gamma 2L$; and the $\alpha 6\beta 3\gamma 2L$ GABA_A receptors are found to be useful.

In a preferred embodiment, the whole-cell patch clamp method is applied to a CHO cell expressing the $\alpha 1\beta 2\gamma 2$ GABA_A receptor.

10 Anxiolytic Drugs

In another aspect the invention relates to the use of the chemical compound of the invention for the manufacture of a pharmaceutical composition for the treatment of anxiolytic disorders.

As defined herein, anxiety disorders include generalised anxiety disorders, panic attacks, phobic disorders, obsessive-compulsive disorders, post-traumatic disorders, and mixed anxiety and depressive disorders.

Pharmaceutical Compositions

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical compound of the invention.

While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.

In a preferred embodiment, the invention provides pharmaceutical compositions comprising the chemical compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefor, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

The pharmaceutical composition of the invention may be administered by any convenient route which suite the desired therapy. Preferred routes of administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition may be prepared by the skilled person using standard and conventional techniques appropriate to the desired formulation.

The actual dosage depend on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is at present contemplated that the pharmaceutical composition of the invention contain, as the active compound, of from about 1 to about 1000 mg of the chemical compound of the invention per individual dose.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is further illustrated by reference to the accompanying drawing, in which:

Fig. 1 shows responses to 0.3, 3, 30 and 300 μM GABA, recorded from a CHO cell expressing GABA_A $\alpha 1\beta 2\gamma 2$ receptors;

Fig. 2 shows the full dose-response curve for GABA, recorded from a CHO cell expressing GABA_A $\alpha 1\beta 2\gamma 2$ receptors (the EC_{50} -value was calculated to 18.8 μM and the Hill coefficient to 1.74);

Fig. 3 shows responses to 6 μM GABA, 1 μM GABA, and 10 μM GABA, recorded in the absence and the presence of 10 μM of a test compound (Compound 6 of Ex. 1), recorded from a CHO cell expressing GABA_A $\alpha 1\beta 2\gamma 2$ receptors;

Fig. 4 shows the effect of 10 μM of a test compound (Compound 6 of Ex. 1) as a function of the GABA concentration, recorded from a CHO cell expressing GABA_A $\alpha 1\beta 2\gamma 2$ receptors;

Fig. 5 shows the effect of 1 μM of a test compound (Compound 6 of Ex. 1) as a function of the GABA concentration, and compared to 1 μM of a classical benzodiazepine agonist (DiazepamTM), recorded from a CHO cell expressing GABA_A $\alpha 1\beta 2\gamma 2$ receptors; and

Fig. 6 shows the simultaneous effect of 10 μ M of a test compound (Compound 6 of Ex. 1) and 3 μ M of a classical benzodiazepine agonist (DiazepamTM), compared the effect of 10 μ M of the test compound alone, recorded from a CHO cell expressing GABA_A α 1 β 2 γ 2 receptors.

5

EXAMPLES

The invention is further illustrated with reference to the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.

10

Example 1

Preparatory Example

5-Acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole O-ethyl oxime (Compound 6)

4-Fluoro-3-nitroacetophenone (Compound 1): Concentrated sulphuric acid (200 ml) is cooled to 5°C. 4-Fluoroacetophenone (20 ml, 0.16 mol) is added keeping the temperature below 10°C. The mixture is cooled to 0-5°C and potassium nitrate (25 g, 0.25 mol) is added portionwise over 2 hours keeping the temperature within this range. Following the addition the mixture is stirred in the cold for additionally 2 hours. The mixture is poured on ice (600 g) and the crude product is filtered off. Column-
20 chromatographic purification on silica gel using a mixture of ethyl acetate and petroleum ether (1:9) as the eluent affords pure Compound 1 (18.2 g, 60%). Mp 48-49°C.

3-(3-Pyridyl)aniline (Compound 2): A mixture of diethyl 3-pyridylborane (16.3 g, 0.11 mol), 3-bromoaniline (12.2 ml, 0.11 mol), potassium carbonate (45.8 g, 0.33 mol) and tetrakis(triphenylphosphine)palladium(0) (80 mg) in a mixture of water (40 ml) and dimethoxyethane (80 ml) is heated to 80°C under a stream of nitrogen over night. After cooling the mixture is diluted with water and ethyl acetate and filtered through a fluted filter paper. The layers are separated. The aqueous layer is extracted once with ethyl acetate. The combined organic phases are dried over sodium sulphate
30 and concentrated under reduced pressure. The residue is dissolved in ethanol. Water is added and the mixture is evaporated to dryness. This residue crystallises upon trituration with ice-cold water. The crystals are collected, dried and washed with petroleum ether to afford pure Compound 2 (16.3g, 87%). Mp 75-76°C.

4-Acetyl-2-nitro-N-(3-(3-pyridyl)phenyl)aniline (Compound 3): A mixture of Compound 1 (5 g, 27.3 mmol) and Compound 2 (4.62 g, 27.2 mmol) in dry N-methyl-2-pyrrolidone (10 ml) is stirred at 40-50°C over night. The resulting solid reaction mixture is suspended in ice-water and rendered alkaline by addition of aqueous sodium carbonate (1M). The product is filtered off, washed with water and dried to yield 7.68 g (Compound 3) (85%). Mp 112-113°C.

5-Acetyl-2-(3-(3-pyridyl)phenylamino)aniline (Compound 4): Compound 3 (2 g, 6 mmol) is suspended in a mixture of ethanol (50 ml) and dichloromethane (10 ml) and is hydrogenated at ambient pressure using palladium (5% on activated carbon) as the catalyst. Filtration of the resulting solution through celite followed by evaporation of solvent leaves an oil. Trituration with a mixture of diethyl ether and petroleum ether (1:1) affords 1.46 g pure Compound 4 (80%). Mp 175-176°C.

5-Acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole (Compound 5): A solution of Compound 4 (7 g, 23.1 mmol) in formic acid (20 ml) is stirred overnight at ambient temperature. The mixture is poured into water (750 ml) and rendered basic with concentrated aqueous ammonia. The precipitate is filtered off, washed with water and dried. The crude product is dissolved in refluxing ethanol. Water is added until onset of precipitation. The mixture is allowed to cool. The product is filtered off and dried to yield 4.3 (60%). Mp. 200 - 202°C.

5-Acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole O-ethyl oxime (Compound 6): Compound 5 (5 g, 15.97 mmol) is suspended in absolute ethanol (50 ml) and heated to 70°C. O-Ethyl hydroxylamine hydrochloride (2.4 g, 24.61 mmol) is added and the mixture is heated to reflux for 1.5 hours. After cooling the solvent is removed by evaporation, and the residue is stirred with aqueous sodium hydroxide (50 ml, 1M). The crude product is filtered off. Column-chromatographic workup on silica gel using a mixture of ethyl acetate and ethanol (9:1) as the eluent affords pure Compound 6. Yield: 3.7g (65%). Mp 105-106°C.

Example 2

Preparation of CHO Cells expressing GABA_A Receptors

Cloning: The cloning of hGABA_A subunits was carried out as follows. Human brain hippocampus poly A⁺ mRNA (Clontech) was reverse transcribed with oligo dT primer and MMLV reverse transcriptase (Pharmacia). 100 ng first strand

cDNA was subjected to PCR using Expand HF polymerase (Boehringer Mannheim) and specific primer sets spanning the full length cDNA sequence. The primer sets were:

1. hGABA_A α_1 : (s) 5'CCTTAGCTGCTCCAGCCCGCGATGAGGA3';
 (as) 5'TTCCCAGTGCAGAGGAACTGAACAACAGAATG3';
2. hGABA_A β_2 : (s) 5'AAACTAAAGGGATGTGGAGAGTGCGGAAAAG3';
 (as) 5'TCCAGTGGGAGGCCATGTTTTAGTTCACATAA3';
3. hGABA_A γ_2 : (s) 5'CTGCAACCAAGAGGCAAGAGGCGAGAG3'; and
 (as) 5'CCATATCAGTAAAACCCATACCTCCTCACAGG3'.

PCR conditions were 1) 94 °C 60 seconds; 2) 15 times (94 °C for 60 seconds, 55°C for 60 seconds, 72°C for 120 seconds); 3) 20 times (94 °C for 60 seconds, 55°C for 60 seconds, 72°C for 180 seconds); 4) 72°C for 10 minutes. The amplified products were polished with *pfu* polymerase (Stratagene), purified on Quiaquick column (Qiagen) and subcloned into pCRScript (Stratagene). Maxiprep DNA (Qiagen) was prepared from positive clones and two to three individual clones of each subunits was sequenced bidirectionally on an ABI 377 sequencer using standard chain termination dyes (Perkin Elmer).

Subcloning: The α_1 -subunit was subcloned into pUbi2z (a custom designed mammalian expression vector using a human ubiquitin promoter to drive the inserted cDNA and the cDNA for enhanced green fluorescence protein (EGFP) fused to the selection marker conferring Zeocin resistance), the β_2 -subunit was subcloned into pNS1n (a custom designed mammalian expression vector using a CMV promoter to drive the inserted cDNA and kanamycin/neomycin selection marker), and the γ_{2s} -subunit was subcloned into pZeoSV (Invitrogen).

A single plasmid containing expression cassettes for both the β_2 subunit and the γ_{2s} -subunit was constructed as follows. The entire expression cassette for the γ_{2s} -subunit in pZeoSV (SV40 promoter, cDNA, SV40-polyA) was excised as a BamHI fragment and subcloned into the BglII site at position 1 in pNS1n/hGABA_A β_2 . A clones in which the driving promoters SV40 and CMV were pointing in opposite directions was selected.

Transfection: For transient transfection experiments 1 μ g of pUbi2z/ α_1 was mixed with 1 μ g of pNS1n/ $\beta_2\gamma_{2s}$ and transfected into Chinese hamster ovary cells

(CHO, ATCC) using lipofectamine (Gibco) according to manufactures instructions. 24 hours after transfection, cells were plated into 35 mm Petri dishes containing 3.5 mm glass coverslips. Cells were kept at 37°C, in 5% CO₂/95% air and used for electrophysiological studies 2-50 hours after plating.

5

Example 3

Patch Clamp Experiments

Electrophysiology: All experiments were performed in voltage clamp using conventional whole cell patch clamp methods. The following salt solutions were used:

10 Extracellular solution (mM): NaCl (140), KCl (4), CaCl₂ (2), MgSO₄ (4), HEPES (10, pH =7.4);

Intracellular solution (mM): CsCl (120), CsF (20), MgSO₄ (4), EGTA (10), ATP (4), HEPES (10, pH = 7.2).

Electronics, programs and data acquisition: The amplifier used was an
15 EPC-9 (HEKA-electronics, Lambrecht, Germany) run by a Macintosh 7600/120 computer via an ITC-16 interface. Experimental conditions were set with the Pulse- software accompanying the amplifier. Data were low pass filtered and sampled directly to hard-disk at a rate of 3 times the cut-off frequency.

Pipettes and electrodes: Pipettes were pulled from borosilicate glass
20 (Modulohm, Copenhagen, Denmark) using a horizontal electrode puller (Zeitz-Instrumente, Augsburg, Germany). The pipette resistance was 1.6 - 2.6 mW in the salt solutions used in these experiments. The pipette electrode was a chloridised silver wire, and the reference was a silverchloride pellet electrode (In Vivo Metric, Healdsburg, USA) fixed to the experimental chamber. The electrodes were zeroed
25 with the open pipette in the bath just prior to sealing.

Experimental procedure: The patch clamp experiments were performed at room temperature (20 - 22 °C).

Coverslips were transferred to a 15 ml experimental chamber mounted on the stage of an inverted microscope (IMT-2, Olympus) supplied with Nomarski optics
30 and a mercury lamp (Olympus). Cells were continuously superfused with extracellular saline at a rate of 2,5 ml/min. Cells chosen for experiments were spherical and emitted bright green fluorescence when exposed to UV-light from the mercury lamp. After

giga-seal formation (1-5 GW, success-rate \approx 90 %) the whole cell configuration was attained by suction.

The cells were held at a holding potential of -60 mV and at the start of each experiment the current was continuously measured for 20 sec to ensure a stable
5 baseline. GABA-containing solutions were delivered to the chamber through a custom-made gravity-driven flowpipe, the tip of which was placed approximately 50 μ m from the cell. Application was triggered by compressing the tubing connected to the flow pipe with a valve controlled by the Pulse-software. In general, GABA was applied for 4 sec. every 30 sec. The sampling interval during application was 1 msec. Having
10 obtained responses of a stable amplitude, the extracellular saline as well as the agonist containing solution were switched to solutions containing the compound (i.e. Compound 6 or Diazepam) to be tested. The compound was present until responses of a stable amplitude were achieved.

Currents were measured at the peak of the responses. Effect of compounds
15 was calculated as the peak current at compound equilibrium divided by the current evoked by the pulse immediately before the compound was included.

The results of these experiments are presented in Figs. 1-6.

In Fig. 1 the cell was voltage clamped at -60 mV and exposed to GABA at
varying concentrations ejected from the flowpipe. The time between pulses was 30
20 sec.

In Fig. 2 the magnitude of the peak currents were expressed as fractions of the peak current obtained with a maximal concentration of GABA. Symbols represent mean \pm SEM, $n=3-10$. The curve is a fit to the Michaelis-Menten equation and the parameters EC₅₀ and n were calculated from the equation.

25 In Fig. 3 the cell was voltage clamped at -60 mV and exposed to 4-sec pulses of 6 μ M GABA every 20 sec. After assessment of the effect of Compound 6 (indicated by the horizontal bar, top panel), the GABA concentration was changed to 1 μ M, and the effect of Compound 6 was evaluated (middle panel). Finally, the effect of Compound 6 on responses evoked by 10 μ M GABA was evaluated (bottom) (please
30 note the different scaling).

In Fig. 4 cells were voltage clamped at -60 mV and exposed to 4-sec pulses of GABA at 0.3-100 μ M. After obtaining responses of a stable amplitude, Compound 6 (10 μ M) was included in the bath-Ringer and in the GABA solutions. When responses

again were stable, solutions were switched back to control. Results are expressed as % of control, referring to the response obtained just before Compound 6 was included (100 % = no effect on peak amplitude). Data points are mean \pm SEM (n=3-10).

In Fig. 5 the cells were voltage clamped at -60 mV and exposed to 4-sec
5 pulses of GABA at 0.3-100 μ M. After obtaining responses of a stable amplitude, Compound 6 (1 μ M, closed symbols) or Diazepam (1 μ M, open symbols) was included in the bath-Ringer and in the GABA solutions. When responses again were stable, solutions were switched back to control. Results are expressed as % of control, referring to the response obtained just before the drug in question was included (100
10 % = no effect on peak amplitude). Data points are mean \pm SEM (n=3-5).

In Fig. 6 the cells were voltage clamped at -60 mV and exposed to 4-sec pulses of 0.3 μ M GABA every 20 sec. After two control responses of the same size, Compound 6 (10 μ M) and Diazepam (3 μ M) were included in the solutions. After one minute (3 responses under the hatched bar), Diazepam was omitted from the
15 solutions. After one minute (3 responses under the open bar only) solutions were changed back to control conditions.

CLAIMS

1. Use of a chemical compound for the manufacture of a pharmaceutical composition for the treatment of anxiolytic disorders, which chemical compound
5 potentiate responses evoked by lower concentrations of GABA, while inhibiting responses evoked by higher concentrations of GABA.
2. The use according to claim 1, in which the chemical compound potentiate responses evoked by concentrations of GABA of below 3 μM , while inhibiting
10 responses evoked by concentrations of GABA of more above 3 μM .
3. The use according to claim 1, in which the chemical compound potentiate responses evoked by concentration of GABA in the range of from about 0.001 to about 10 μM , more preferred in the range of from about 0.1 to about 5 μM , most
15 preferred in the range of from about 0.3 to about 3 μM .
4. The use according to claim 1, in which the chemical compound inhibit responses evoked by concentrations of GABA of more than about 50 μM , more preferred of more than about 10 μM , yet more preferred of more than about 5 μM , most
20 preferred of more than about 3 μM .
5. A method for the screening of chemical compounds for their potential as anxiolytic drugs, which method comprises the steps of
 - (i) determining, in the presence of different concentrations of GABA, the
25 electrophysiological response evoked by GABA on a GABA_A receptor;
 - (ii) repeating step (i) in the presence of a chemical compound to be screened; and
 - (iii) selecting the chemical compounds that selectively potentiate responses evoked by GABA at lower concentrations.
- 30 6. The method according to claim 5, wherein, in steps (i) and (ii), the concentration of GABA range of from about 0.001 μM to about 10,000 μM , preferably of from

about 0.01 μM to about 1000 μM , more preferred of from about 0.1 μM to about 500 μM , most preferred of from about 0.3 μM to about 300 μM .

7. The method according to claim 5, wherein in step (iii) chemical compounds that
5 selectively potentiate responses evoked by GABA at concentrations lower than 5 μM , preferably lower than 3 μM , are selected.
8. The method according to any of claims 5-7, wherein the determination of the
10 electrophysiological response in step (i) and (ii) is performed by voltage clamp using whole cell patch clamp methods.
9. The method according to claim 8, wherein the GABA_A receptor is located on a CHO cell, a HEK cell, or a HeLa cell.
- 15 10. The method according to claim 9, wherein the cell is expressing the $\alpha 1\beta 2\gamma 2$; the $\alpha 1\beta 2\gamma 2\text{L}$; the $\alpha 1\beta 3\gamma 2\text{L}$; the $\alpha 2\beta 2\gamma 2\text{L}$; the $\alpha 2\beta 3\gamma 2\text{L}$; the $\alpha 3\beta 2\gamma 2\text{L}$; the $\alpha 3\beta 3\gamma 2\text{L}$; the $\alpha 5\beta 2\gamma 2\text{L}$; the $\alpha 5\beta 3\gamma 2\text{L}$; the $\alpha 6\beta 2\gamma 2\text{L}$; or the $\alpha 6\beta 3\gamma 2\text{L}$ GABA_A receptor.
11. The method according to claim 9, wherein cell is a CHO cell expressing the
20 $\alpha 1\beta 2\gamma 2$ GABA_A receptor.
12. A chemical compound having anxiolytic activity identified by the method according to any of claims 5-11.
- 25 13. A chemical compound capable of potentiating responses evoked by lower concentrations of GABA, while inhibiting responses evoked by higher concentrations of GABA.
14. The chemical compound of claim 13, which is capable of potentiating responses
30 evoked by concentrations of GABA of below 3 μM , while inhibiting responses evoked by concentrations of GABA of more above 3 μM .

15. The chemical compound of either of claims 13-14 for use as a non-sedative anxiolytic drug.
16. A pharmaceutical composition comprising the chemical compound of any of
5 claims 12-15.
17. A method of treating an anxiolytic disorder, by which method a mammal, including a human, is treated with a chemical compound according to any of
10 claims 12-15.

1/6

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, G01N 33/566	A3	(11) International Publication Number: WO 99/29319 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/DK98/00489 (22) International Filing Date: 13 November 1998 (13.11.98) (30) Priority Data: 1433/97 9 December 1997 (09.12.97) DK (71) Applicant (for all designated States except US): NEUROSEARCH A/S [DK/DK]; Smedeland 26B, DK-2600 Glostrup (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): VARMING, Thomas [DK/DK]; NeuroSearch a/s, Smedeland 26B, DK-2600 Glostrup (DK). (74) Common Representative: NEUROSEARCH A/S; Patent Dept., Smedeland 26B, DK-2600 Glostrup (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 22 July 1999 (22.07.99)
(54) Title: CHEMICAL COMPOUNDS FOR USE AS ANXIOLYTIC AGENTS AND A METHOD FOR THE IDENTIFICATION OF ANXIOLYTIC COMPOUNDS (57) Abstract <p>This invention relates to a particular group of chemical compounds for use as non-sedative anxiolytic drugs, and a method for the identification of chemical compounds with anxiolytic potential.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 98/00489

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/44 G01N33/566

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 96 33191 A (NEUROSEARCH AS ;MEIJI SEIKA KAISHA (JP); TEUBER LENE (DK); WAETJEN)</p> <p>24 October 1996</p> <p>see abstract</p> <p>see page 1, line 4 - page 2, line 33</p> <p>see page 8, line 15 - page 10, line 6</p> <p>see table 9, 2nd compound</p> <p>see page 14, line 14 - line 30</p> <p>see table 1, compound 33a</p> <p>see claims 1-10</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-4, 13-17</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

8 April 1999

Date of mailing of the international search report

04 06.99

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 98/00489

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 130 430 A (SHAW KENNETH) 14 July 1992</p> <p>see abstract see column 1, line 8 - line 18 see column 4, line 24 - line 51 see column 6, line 25 - column 7, line 39 see column 10, line 3 - line 38 see table 1 see column 10, line 48 - line 59</p> <p style="text-align: center;">---</p>	1-4, 13-17
P,X	<p>WO 98 17651 A (TEUBER LENE ;WAETJEN FRANK (DK); NEUROSEARCH AS (DK)) 30 April 1998</p> <p>see abstract see page 2, line 20 - line 25 see page 12, line 7 - line 24 see page 15, line 18 - page 16, line 15 see page 20, line 17 - line 31 see page 24, line 28 - page 25, line 24 see page 66, line 24 - page 69, line 12</p> <p style="text-align: center;">---</p>	1-4, 13-17
P,X	<p>WO 98 34923 A (MERCK SHARP & DOHME ;HARRISON TIMOTHY (GB); SPAREY TIMOTHY JASON ()) 13 August 1998</p> <p>see abstract see page 1, line 4 - line 8 see page 2, line 4 - page 3, line 25 see page 4, line 20 - page 5, line 8 see page 11, line 11 - line 15 see page 19, line 30 - page 20, line 2 see claims 1-12</p> <p style="text-align: center;">---</p>	1-4, 13-17
E	<p>EP 0 889 044 A (ORTHO MCNEIL PHARMACEUTICAL IN) 7 January 1999</p> <p>see abstract see page 2, line 5 - line 24 see table 1</p> <p style="text-align: center;">---</p>	1-4, 13-17
A	<p>MARYANOFF B E ET AL: "POTENTIAL ANIOLYTIC AGENTS. 2. IMPROVEMENT OF ORAL EFFICACY FOR THEPYRIDO 1,2-ABENZIMIDAZOLE (PBI) CLASS OF GABA-A RECEPTOR MODULATORS" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 3, 1996, pages 333-338, XP002054104</p> <p>see the whole document</p> <p style="text-align: center;">---</p>	1-4, 13-17
A	<p>MARYANOFF B E ET AL: "POTENTIAL ANXIOLYTIC AGENTS. PYRIDOL 1,2-ABENZIMIDAZOLES: A NEW STRUCTURAL CLASS OF LIGANDS FOR THE BENZODIAZEPINE BINDING SITE ON GABA-A RECEPTORS" JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 1995, pages 16-20, XP002053732</p> <p>see introduction see conclusion</p> <p style="text-align: center;">-----</p>	1-4, 13-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 98/00489

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-4, 13-15, 16(in part), 17(in part)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-4, 13-15, 16 (in part), 17 (in part)

Use of compounds which potentiate responses evoked by lower concentrations of GABA, while inhibiting responses evoked by higher concentrations of GABA for the treatment of anxiolytic disorders.

2. Claims: 5-12, 16 (in part), 17 (in part)

Screening methods.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 98/00489

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9633191 A	24-10-1996	AU 5501496 A	07-11-1996
		AU 695957 B	27-08-1998
		AU 5689196 A	07-11-1996
		AU 699623 B	10-12-1998
		AU 5690696 A	07-11-1996
		CA 2217601 A	24-10-1996
		CA 2218493 A	24-10-1996
		CA 2218552 A	24-10-1996
		CN 1182427 A	20-05-1998
		CN 1182426 A	20-05-1998
		CN 1182425 A	20-05-1998
		CZ 9703291 A	18-03-1998
		CZ 9703292 A	18-03-1998
		WO 9633194 A	24-10-1996
		WO 9633192 A	24-10-1996
		EP 0821683 A	04-02-1998
		EP 0821684 A	04-02-1998
		EP 0821682 A	04-02-1998
		JP 11501320 T	02-02-1999
		JP 11501321 T	02-02-1999
		NO 974843 A	15-12-1997
		NO 974844 A	16-12-1997
		NZ 307521 A	29-04-1999
		NZ 307532 A	29-03-1999
		PL 322892 A	02-03-1998
		PL 322944 A	02-03-1998
		SK 139997 A	06-05-1998
		SK 140697 A	06-05-1998
US 5130430 A	14-07-1992	CA 2094805 C	26-12-1995
		CN 1076930 A,B	06-10-1993
		EP 0555391 A	18-08-1993
		JP 6502639 T	24-03-1994
		WO 9207853 A	14-05-1992
		US 5744602 A	28-04-1998
WO 9817651 A	30-04-1998	AU 4616197 A	15-05-1998
WO 9834923 A	13-08-1998	AU 5874498 A	26-08-1998
EP 0889044 A	07-01-1999	AU 7395098 A	07-01-1999
		AU 7589298 A	19-01-1999
		CA 2242261 A	30-12-1998
		WO 9900389 A	07-01-1999